Chen Qi, Yao Xingmei, Quan Jiali, Jia Xinhua, Li Yufei, Zhu Kongxin, Hu Xiaowen, Huang Xingcheng, Zhong Guohua, Qiu Lingxian, Bi Zhaofeng, Liao Mengjun, Chen Lu, Kuang Xuefeng, Wang Zhe, Hu Shangying, Zhuang Chunlan, Huang Shoujie, Wei Lihui, Chen Wen, Su Yingying, Zhao Fanghui, Wu Ting, Qiao Youlin, Zhang Jun, Xia Ningshao
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, Fujian Province, China.
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, Xiamen University, Xiamen, Fujian Province, China.
Int J Cancer. 2025 Mar 1;156(5):1043-1054. doi: 10.1002/ijc.35290. Epub 2024 Dec 13.
Data investigating the natural history of high-risk human papillomavirus (HR-HPV) infection in mid-adult women compared with young adult women from regions exhibiting a bimodal distribution pattern are scarce. From November 2012 to September 2019, 3681 healthy women aged 18-45 years from the control group of a bivalent HPV vaccine Phase 3 trial in China were followed over 5.5 years. At scheduled visits (Day 0, months 7, 12, 18, 24, 30, 42, 54, and 66), cervical samples were collected for ThinPrep Pap tests and HPV DNA testing, women with abnormal cytology were referred for colposcopy. Data was analyzed using Cox regression model and a competing risk model. Sensitivity analyses were performed among participants attending all scheduled visits. The incidences of HR-HPV persistent infections (over 6 months [6mPIs]) were 35.5 and 29.0 per 1000 person-years (PYs) (hazard ratio [HR] = 1.21, 95% confidence interval [CI]: 1.00, 1.46), and HR-HPV associated CIN grade 2 or greater (CIN2+) were 4.3 and 1.9 per 1000 PYs (HR = 2.31, 95% CI: 1.25, 4.26) in women aged 18-26 and 27-45 years. Competing risk models showed that the cumulative incidence of HR-HPV infections that progressed to CIN2+ was significantly higher in women aged 18-26 than in women aged 27-45 (5.3% vs. 2.9%, Gray's test p = .0291). The cumulative clearance rates of HR-HPV infections in women aged 18-26 and 27-45 were similar (94.7% vs. 95.8%, Gray's test p = .3309) during the study period. In conclusion, although mid-adult women exhibit lower incidences of HR-HPV infection and associated cervical lesions compared to young women, this population continues to face a substantial risk of acquiring causal HPV infections, which may progress to cervical lesion.
与来自呈现双峰分布模式地区的年轻成年女性相比,关于中年成年女性高危人乳头瘤病毒(HR-HPV)感染自然史的数据较少。2012年11月至2019年9月,对中国一项二价HPV疫苗3期试验对照组的3681名18至45岁健康女性进行了5.5年的随访。在预定访视(第0天、第7、12、18、24、30、42、54和66个月)时,采集宫颈样本进行薄层液基细胞学检测和HPV DNA检测,对细胞学异常的女性进行阴道镜检查。使用Cox回归模型和竞争风险模型分析数据。在参加所有预定访视的参与者中进行敏感性分析。18至26岁和27至45岁女性中,HR-HPV持续感染(超过6个月[6mPIs])的发病率分别为每1000人年35.5例和29.0例(风险比[HR]=1.21,95%置信区间[CI]:1.00,1.46),HR-HPV相关的2级或更高级别宫颈上皮内瘤变(CIN2+)分别为每1000人年4.3例和1.9例(HR=2.31,95%CI:1.25,4.26)。竞争风险模型显示,进展为CIN2+的HR-HPV感染累积发病率在18至26岁女性中显著高于27至45岁女性(5.3%对2.9%,Gray检验p=0.0291)。在研究期间,18至26岁和27至45岁女性中HR-HPV感染的累积清除率相似(94.7%对95.8%,Gray检验p=0.3309)。总之,尽管中年成年女性与年轻女性相比HR-HPV感染及相关宫颈病变的发病率较低,但该人群仍面临感染致病性HPV的重大风险,这可能进展为宫颈病变。